Partial
Partial Aligned
Patient Risk:
Moderate
Summary
The provided label excerpt supports patient evaluation/monitoring for gabapentin misuse/abuse, but many other listed statements (e.g., specific misuse purposes, DEA classification, prevalence in seizures/toxicology, and specific risk assertions like dependence/withdrawal) are not supported by the supplied prescribing-information text and therefore cannot be confirmed.
Category Scores
Accurate Statements
Gabapentin abuse/misuse has been reported; evaluate patients for history of drug abuse and signs of misuse/abuse.
Supported by section 9.2 Abuse: gabapentin misuse/abuse have been reported postmarketing; prescribers should carefully evaluate patients for a history of drug abuse and observe for signs/symptoms of misuse/abuse (e.g., self-dose escalation, drug-seeking behavior).
Unsupported Statements
Gabapentin is subject to misuse and diversion.
Not supported by the supplied label excerpts (9.2 Abuse; 5.8 Respiratory Depression; 5.4 Somnolence/Sedation and Dizziness; 10 Overdosage; 1 Indications and Usage; 2.1/14.2).
Gabapentin misuse is reported to be often for recreational purposes.
Not supported by the supplied label excerpts.
Gabapentin misuse can include using the drug to achieve a euphoric high.
Not supported by the supplied label excerpts.
Gabapentin misuse can include self-medicating for withdrawal symptoms from other drugs.
Not supported by the supplied label excerpts.
Gabapentin can produce euphoric effects in some individuals.
Not supported by the supplied label excerpts.
The U.S. Drug Enforcement Administration (DEA) classifies gabapentin as a drug of concern due to its abuse potential.
Not supported by the supplied label excerpts.
Individuals with a history of substance use disorders are more likely to misuse gabapentin.
Not supported by the supplied label excerpts (9.2 references history of polysubstance abuse in reported cases, but the statement is broader and not directly stated).
Gabapentin is prevalent in drug seizures.
Not supported by the supplied label excerpts.
Gabapentin is found in toxicology reports associated with overdose deaths.
Not supported by the supplied label excerpts.
Gabapentin is often found in combination with other illicit or prescription drugs in overdose contexts.
Not supported by the supplied label excerpts.
Misusing gabapentin can lead to respiratory depression.
While 5.8 and 10 mention respiratory depression/fatal respiratory depression with coadministration with CNS depressants and in overdose contexts, the statement specifically frames it as a consequence of 'misusing' (not directly supported as stated).
Misusing gabapentin can lead to central nervous system depression.
Not supported directly in the provided excerpts as a consequence of 'misusing'; 5.4 discusses CNS depression monitoring with sedative co-use.
Misusing gabapentin can lead to potentially fatal overdose.
The provided excerpts discuss fatal respiratory depression in overdose contexts, but not 'misuse' leading to fatal overdose as a general claim.
The risk of fatal overdose with gabapentin misuse is increased when mixed with other sedating substances.
Not stated in the provided excerpts as an increased risk due to 'misuse'; 5.8 discusses associations when coadministered with CNS depressants.
Dependence can occur with gabapentin misuse.
Not supported by the supplied label excerpts.
Withdrawal symptoms can occur with gabapentin misuse.
Not supported by the supplied label excerpts.
Gabapentin can produce sedative effects in some individuals.
Not supported directly in the provided excerpts as a general statement; 5.4 discusses somnolence/sedation rates and monitoring.
Gabapentin sedative and euphoric effects may be more likely at higher doses.
Not supported by the supplied label excerpts; 5.4 provides somnolence/sedation incidence in trials but does not address 'euphoric effects' or dose-likelihood formulation as stated.
Gabapentin sedative and euphoric effects may be more likely when combined with other substances like opioids.
5.8/5.4 support monitoring and associations with opioids/CNS depressants for respiratory depression/sedation, but the inclusion of 'euphoric effects' is not supported.
Gabapentin sedative and euphoric effects may be more likely when combined with other substances like alcohol.
Not supported by the supplied label excerpts (no alcohol-specific statements provided).
Gabapentin is FDA-approved to treat partial seizures in epilepsy.
The provided label excerpt (14.2) supports adjunctive therapy for partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older (not general 'treat partial seizures' wording).
Gabapentin is FDA-approved for neuropathic pain associated with postherpetic neuralgia.
Not supported because the supplied indications excerpt is for management of postherpetic neuralgia in adults; neuropathic pain wording is not directly stated in the provided excerpt.
Gabapentin has off-label uses.
Whether off-label uses exist is not stated in the supplied label excerpts.
Off-label uses of gabapentin include treatment for anxiety.
Not supported by the supplied label excerpts.
Off-label uses of gabapentin include treatment for restless legs syndrome.
Not supported by the supplied label excerpts.
Off-label uses of gabapentin include treatment for alcohol withdrawal symptoms.
Not supported by the supplied label excerpts.
Gabapentin was originally marketed as Neurontin.
Not supported by the supplied label excerpts.
Gabapentin is long off-patent.
Not supported by the supplied label excerpts.
Generic versions of gabapentin have been available for many years.
Not supported by the supplied label excerpts.
Misuse can be contributed to by gabapentin off-label uses.
Not supported by the supplied label excerpts (9.2 notes higher than recommended doses for unapproved uses in some reports, but not that off-label uses contribute to misuse generally as stated).
Misuse can be contributed to by gabapentin's inherent effects.
Not supported by the supplied label excerpts.
For neuropathic pain, pregabalin is an alternative to gabapentin.
Not supported by the supplied label excerpts.
For neuropathic pain, certain antidepressants such as duloxetine are alternatives to gabapentin.
Not supported by the supplied label excerpts.
For neuropathic pain, topical agents like lidocaine patches are alternatives to gabapentin.
Not supported by the supplied label excerpts.
For seizure disorders, a wide range of antiepileptic drugs are available.
Not supported by the supplied label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
If discussing respiratory depression risk with coadministration, the label excerpt specifies evaluating/monitoring for symptoms of respiratory depression and sedation and considering low-dose initiation; the provided list does not reflect these prescriber actions or the conditional nature ('when coadministered with CNS depressants... or underlying respiratory impairment').
Importance:
Moderate
Where somnolence/sedation is discussed, the label excerpt provides comparative incidence and notes discontinuations in trials; the provided list does not capture the trial-based rates or discontinuation linkage.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Many statements about abuse/misuse mechanisms, prevalence, regulatory classification, and consequences (e.g., dependence/withdrawal; recreational/euphoric effects; alcohol-specific combinations) are not supported by the supplied label excerpts. Overstating or inserting unsupported details could mislead risk characterization, though the core label-supported monitoring/evaluation statement is included.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial Aligned
Primary Issue
Large portions of the listed claims are not supported by the provided prescribing-information excerpts (notably DEA classification, seizure/toxicology prevalence, recreational/euphoric framing, dependence/withdrawal, and multiple off-label indications).
Suggested Improvement
Limit abuse/misuse content to what the label excerpt states: postmarketing reports of misuse/abuse, the presence of polysubstance abuse histories in reports, and the prescriber instruction to evaluate for drug abuse history and observe for misuse/abuse signs (e.g., self-dose escalation, drug-seeking behavior). For respiratory depression/sedation, present the label’s conditional coadministration/underlying impairment framing and the recommended monitoring/low-dose consideration.